News
Cogent Biosciences said its experimental drug reduced the symptoms of a chronic immune disorder called indolent systemic ...
WASHINGTON — The steady erosion of experienced staff at the Food and Drug Administration is slowly compromising the agency’s ...
The steady erosion of experienced staff is slowly compromising FDA work and low morale is pushing more workers to the exit ...
President Trump and Republicans’ tax law is one of the most significant pieces of health care legislation since the ACA. It ...
Apogee Therapeutics said its antibody treatment alleviated signs and symptoms of atopic dermatitis far more than a placebo — ...
As Chinese-developed drugs draw U.S. interest, a regulatory chill threatens to dampen new investment
Those questions, experts say, are based on the Trump administration’s hawkish approach to China generally, as well as on a ...
Ananda Lewis should still be alive. She had access. She had options. What she didn’t have was trust in the system that could ...
Efforts to eliminate pass-fail grading in medical schools are misguided attempts to undermine the value of a diverse ...
Cogent Biosciences reported results from a Phase 3 study of bezuclastinib in indolent systemic mastocytosis, the most common form of an immune system disorder that causes allergic-like skin reactions, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback